SHIFT Newsroom · GLOBAL
Stopping semaglutide in type 1 diabetes: a small extension study
This small extension examined glycaemic changes after semaglutide withdrawal in adults with type 1 diabetes using automated insulin delivery. Its findings are specific to that specialist setting and do not support an independent change to insulin or another medicine.
What the source says
This small extension examined glycaemic changes after semaglutide withdrawal in adults with type 1 diabetes using automated insulin delivery. Its findings are specific to that specialist setting and do not support an independent change to insulin or another medicine.
Evidence and limits
The 12-week extension compared 16 people who stopped semaglutide with 22 previous placebo participants. Glucose time in range and variability worsened after withdrawal in this particular setting. These findings are not instructions to stop treatment or change insulin independently.
What we checked
We checked the primary publication record and available abstract. The full paper and supplements have not been reviewed for this correction.
SHIFT’s take
Anyone using insulin needs their diabetes team involved in treatment changes. This small study is specialist evidence, not a self-management protocol.
Known facts
- This small extension examined glycaemic changes after semaglutide withdrawal in adults with type 1 diabetes using automated insulin delivery.